ArticleBMJ open2026
Accuracy of nanopore sequencing technology for rapid diagnosis of tuberculous mediastinal and hilar lymphadenopathy using endobronchial ultrasound-guided transbronchial needle aspiration specimens: protocol for a systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAccessing samples from mediastinal and hilar lymph nodes is considerably more difficult, rendering the diagnosis of tuberculous mediastinal and hilar lymphadenopathy particularly challenging. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive interventional technique used for sampling mediastinal and hilar lymph nodes. Nanopore sequencing technology (NST) permits the rapid identification of METHODS AND ANALYSIS: Adhering to Preferred Reporting Items for a Systematic Review and Meta-Analysis Protocols (PRISMA-P) and PRISMA-Diagnostic Test Accuracy Studies (DTA) guidelines, this protocol (PROSPERO: CRD420251274529) will synthesise evidence from five international databases (PubMed, Embase, SCOPUS, Web of Science and Cochrane Library) and two Chinese databases (China National Knowledge Infrastructure and Wanfang Database). The literature search is planned to be conducted between 1 December 2026 and 31 December 2026 (start and end dates of the search). The publication dates of the included literature ranged from the inception of the relevant databases to 31 December 2026. Data extraction from the included studies is anticipated to be completed by 31 May 2027, and the final reporting of findings is expected by 31 December 2027. Study selection followed the PICT framework: participants (P): patients with suspected tuberculous mediastinal and hilar lymphadenopathy; index test (I): the index test was defined as NST; comparator (C): the reference standard for tuberculous lymphadenopathy; target condition (T): the target condition was confirmed tuberculous mediastinal and hilar lymphadenopathy. Two independent investigators will perform a three-step screening process, extract data and assess methodological quality using Quality Assessment of Diagnostic Accuracy Studies. Bivariate random-effects models implemented in STATA V.15.0 will be used to pool sensitivity, specificity and hierarchical summary receiver operating characteristic curves when four or more studies are available; for fewer studies, Meta-DiSc V.1.4 will be employed. If substantial heterogeneity is detected (I² statistic >50%), meta-regression and subgroup analysis will be performed across prespecified covariates. ETHICS AND DISSEMINATION: This study is based on publicly available data and therefore does not require ethics committee approval. Upon completion, the findings will be submitted for publication in a peer-reviewed medical journal. The review is conducted in accordance with established guidelines for systematic review and meta-analysis. PROSPERO REGISTRATION NUMBER: CRD420251274529.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.